Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Brennan Doyle - Head of Investor Relations Jeffrey Dayno - President & Chief Executive Officer Jeffrey Dierks - Chief Commercial Officer Kumar Budur - Chief Medical Officer & Scientific Officer Sandip Kapadia - Chief Financial Officer & Chief Administrative Officer Conference Call Participants Graig Suvannavejh - Mizuho Ami Fadia - Needham Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Danielle Brill - Raymond James Ash Verma - UBS Corinne Johnson - Goldman Sachs Jason Gerberry - Bank of America Francois Brisebois - Oppenheimer Operator Good morning. My name is Todd, and I will be your conference operator today.
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Surpass Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.63 per share a year ago.
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
Harmony Biosciences stock jumped Tuesday on the biotech company's "high-quality" third-quarter beat on the back of its narcolepsy drug.
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy?
Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HRMY ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Did Harmony Biosciences Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- HRMY
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Harmony Biosciences Holdings, Inc. (HRMY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Investors who Lost Money on Harmony Biosciences Holdings, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - HRMY
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Lost Money on Harmony Biosciences Holdings, Inc. (HRMY)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
